The 2024-2025 mRNA COVID-19 vaccine provided moderate protection against severe outcomes, including hospitalizations and ED visits.
A fourth dose of bivalent or monovalent BA.1-adapted BNT162b2 vaccines was safe and elicited robust neutralizing responses in adults aged 18 to 55 years.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results